Browse by Journal Title

2024

Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes.
Noerenberg, D., Briest, F., Hennch, C., Yoshida, K., Hablesreiter, R., Takeuchi, Y., Ueno, H., Staiger, A.M., Ziepert, M., Asmar, F., Locher, B.N., Toth, E., Weber, T., Amini, R.M., Klapper, W., Bouzani, M., Poeschel, V., Rosenwald, A., Held, G., Campo, E., Ishaque, N., Stamatopoulos, K., Kanellis, G., Anagnostopoulos, I., Bullinger, L., Goldschmidt, N., Zinzani, P.L., Bödör, C., Rosenquist, R., Vassilakopoulos, T.P., Ott, G., Ogawa, S. and Damm, F.
Journal of Clinical Oncology 42 (4): 452-466. 1 February 2024

2023

Consensus molecular subtypes as biomarkers of fluorouracil and folinic acid maintenance therapy with or without panitumumab in (RAS) wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212).
Stahler, A., Hoppe, B., Na, I.K., Keilholz, L., Müller, L., Karthaus, M., Fruehauf, S., Graeven, U., Fischer von Weikersthal, L., Goekkurt, E., Kasper, S., Kind, A.J., Kurreck, A., Alig, A.H.S., Held, S., Reinacher-Schick, A., Heinemann, V., Horst, D., Jarosch, A., Stintzing, S., Trarbach, T. and Modest, D.P.
Journal of Clinical Oncology 41 (16): 2975-2987. 1 June 2023

Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin Lymphoma: final analysis of the randomized german Hodgkin study group phase II NIVAHL trial.
Bröckelmann, P.J., Bühnen, I., Meissner, J., Trautmann-Grill, K., Herhaus, P., Halbsguth, T.V., Schaub, V., Kerkhoff, A., Mathas, S., Bormann, M., Dickhut, A., Kaul, H., Fuchs, M., Kobe, C., Baues, C., Borchmann, P., Engert, A. and von Tresckow, B.
Journal of Clinical Oncology 41 (6): 1193-1199. 20 February 2023

2019

Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation.
Frick, M., Chan, W., Arends, C.M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., Galan-Sousa, J., Noerenberg, D., Wais, V., Stadler, M., Yoshida, K., Schetelig, J., Schuler, E., Thol, F., Clappier, E., Christopeit, M., Ayuk, F., Bornhäuser, M., Blau, I.W., Ogawa, S., Zemojtel, T., Gerbitz, A., Wagner, E.M., Spriewald, B.M., Schrezenmeier, H., Kuchenbauer, F., Kobbe, G., Wiesneth, M., Koldehoff, M., Socié, G., Kroeger, N., Bullinger, L., Thiede, C. and Damm, F.
Journal of Clinical Oncology 37 (5): 375-385. 10 February 2019

2017

Genomics of acute myeloid leukemia diagnosis and pathways.
Bullinger, L., Döhner, K. and Döhner, H.
Journal of Clinical Oncology 35 (9): 934-946. 20 March 2017

2016

How to manage the obese patient with cancer.
Renehan, A.G., Harvie, M., Cutress, R.I., Leitzmann, M., Pischon, T., Howell, S. and Howell, A.
Journal of Clinical Oncology 34 (35): 4284-4294. 10 December 2016

Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma.
Korfel, A., Schlegel, U., Herrlinger, U., Dreyling, M., Schmidt, C., von Baumgarten, L., Pezzutto, A., Grobosch, T., Kebir, S., Thiel, E., Martus, P. and Kiewe, P.
Journal of Clinical Oncology 34 (15): 1757-1763. 20 May 2016

2015

Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial.
Pelzer, U., Opitz, B., Deutschinoff, G., Stauch, M., Reitzig, P.C., Hahnfeld, S., Mueller, L., Grunewald, M., Stieler, J.M., Sinn, M., Denecke, T., Bischoff, S., Oettle, H., Doerken, B. and Riess, H.
Journal of Clinical Oncology 33 (18): 2028-2034. 20 June 2015

2014

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer : outcomes from the CONKO-003 trial.
Oettle, H., Riess, H., Stieler, J.M., Heil, G., Schwaner, I., Seraphin, J., Goerner, M., Moelle, M., Greten, T.F., Lakner, V., Bischoff, S., Sinn, M., Doerken, B. and Pelzer, U.
Journal of Clinical Oncology 32 (23): 2423-2429. 10 August 2014

2013

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
Pellagatti, A., Benner, A., Mills, K.I., Cazzola, M., Giagounidis, A., Perry, J., Malcovati, L., Della Porta, M.G., Jädersten, M., Verma, A., McDonald, E.J., Killick, S., Hellström-Lindberg, E., Bullinger, L., Wainscoat, J.S. and Boultwood, J.
Journal of Clinical Oncology 31 (28): 3557-3564. 1 October 2013

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz, C.W., Pinto, A., Linkesch, W., Lindén, O., Viardot, A., Keller, U., Hess, G., Lastoria, S., Lerch, K., Frigeri, F., Arcamone, M., Stroux, A., Frericks, B., Pott, C. and Pezzutto, A.
Journal of Clinical Oncology 31 (3): 308-313. 20 January 2013

2011

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin study group.
Borchmann, P., Haverkamp, H., Diehl, V., Cerny, T., Markova, J., Ho, A.D., Eich, H.T., Mueller-Hermelink, H.K., Kanz, L., Greil, R., Rank, A., Paulus, U., Smardova, L., Huber, C., Doerken, B., Nerl, C., Krause, S.W., Mueller, R.P., Fuchs, M. and Engert, A.
Journal of Clinical Oncology 29 (32): 4234-4342. 10 November 2011

Pathogenesis of non-Hodgkin's lymphoma.
Nogai, H., Doerken, B. and Lenz, G.
Journal of Clinical Oncology 29 (14): 1803-1811. 10 May 2011

2010

Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954.
Schuhmacher, C., Gretschel, S., Lordick, F., Reichardt, P., Hohenberger, W., Eisenberger, C.F., Haag, C., Mauer, M.E., Hasan, B., Welch, J., Ott, K., Hoelscher, A., Schneider, P.M., Bechstein, W., Wilke, H., Lutz, M.P., Nordlinger, B., Van Cutsem, E., Siewert, J.R. and Schlag, P.M.
Journal of Clinical Oncology 28 (35): 5210-5218. 10 December 2010

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich, H.T., Diehl, V., Goergens, H., Pabst, T., Markova, J., Debus, J., Ho, A., Doerken, B., Rank, A., Grosu, A.L., Wiegel, T., Karstens, J.H., Greil, R., Willich, N., Schmidberger, H., Doehner, H., Borchmann, P., Mueller-Hermelink, H.K., Mueller, R.P. and Engert, A.
Journal of Clinical Oncology 28 (27): 4199-4206. 20 September 2010

2009

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert, A., Diehl, V., Franklin, J., Lohri, A., Doerken, B., Ludwig, W.D., Koch, P., Haenel, M., Pfreundschuh, M., Wilhelm, M., Truemper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Mueller-Hermelink, H.K., Hasenclever, D. and Loeffler, M.
Journal of Clinical Oncology 27 (27): 4548-4554. 20 September 2009

2006

Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer.
Ghadjar, P., Coupland, S.E., Na, I.K., Noutsias, M., Letsch, A., Stroux, A., Bauer, S., Buhr, H.J., Thiel, E., Scheibenbogen, C. and Keilholz, U.
Journal of Clinical Oncology 24 (12): 1910-1916. 20 April 2006

Vascular endothelial growth factor-D and its receptor VEGFR-3: Two novel independent prognostic markers in gastric adenocarcinoma.
Juettner, S., Wissmann, C., Joens, T., Vieth, M., Hertel, J., Gretschel, S., Schlag, P.M., Kemmner, W. and Hoecker, M.
Journal of Clinical Oncology 24 (2): 228-240. 10 January 2006

2005

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Thuss-Patience, P.C., Kretzschmar, A., Repp, M., Kingreen, D., Hennesser, D., Micheel, S., Pink, D., Scholz, C., Doerken, B. and Reichardt, P.
Journal of Clinical Oncology 23 : 494-501. 1 January 2005

2003

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Buechner, T., Hiddemann, W., Berdel, W.E., Woermann, B., Schoch, C., Fonatsch, C., Loeffler, H., Haferlach, T., Ludwig, W.D., Maschmeyer, G., Staib, P., Aul, C., Grueneisen, A., Lengfelder, E., Frickhofen, N., Kern, W., Serve, H.L., Mesters, R.M., Sauerland, M.C. and Heinecke, A.
Journal of Clinical Oncology 21 : 4496-4504. 15 December 2003

Extravasations of oxaliplatin.
Kretzschmar, A., Pink, D., Thuss-Patience, P., Doerken, B., Reichert, P. and Eckert, R.
Journal of Clinical Oncology 21 (21): 4068-4069. 1 November 2003

Dynamic expression profile of p21 WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
Rau, B., Sturm, I., Lage, H., Berger, S., Schneider, U., Haupfmann, S., Wust, P., Riess, H., Schlag, P.M., Doerken, B. and Daniel, P.T.
Journal of Clinical Oncology 21 (18): 3391-3401. 15 September 2003

Acute hypokalemic tetraparesis induced by intravenous methotrexate.
Thuss-Patience, P.C., Peters, U., Jurkat-Rott, K., Pink, D., Kretzschmar, A., Doerken, B. and Reichardt, P.
Journal of Clinical Oncology 21 (9): 1896-1897. 1 May 2003

Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach, T., Schoch, C., Loeffler, H., Gassmann, W., Kern, W., Schnittger, S., Fonatsch, C., Ludwig, W.D., Wuchter, C., Schlegelberger, B., Staib, P., Reichle, A., Kubica, U., Eimermacher, H., Balleisen, L., Grueneisen, A., Haase, D., Aul, C., Karow, J., Lengfelder, E., Woermann, B., Heinecke, A., Sauerland, M.C., Buechner, T. and Hiddemann, W.
Journal of Clinical Oncology 21 : 256-265. 15 January 2003

2002

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Lakhani, S.R., Van de Vijver, M.J., Jacquemier, J., Anderson, T.J., Osin, P.P., McGuffog, L., Easton, D.F., Scherneck, S. and Seitz, S.
Journal of Clinical Oncology 20 (9): 2310-2318. 1 May 2002

Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients.
Stein, U., Juerchott, K., Schlafke, M. and Hohenberger, P.
Journal of Clinical Oncology 20 (15): 3282-3292. 1 January 2002

2001

Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: High BAX and p16(nk4a/CDKN2) identifies patients with good prognosis.
Sturm, I., Petrowsky, H., Volz, R., Lorenz, M., Radetzki, S., Hillebrand, T., Wolff, G., Hauptmann, S., Doerken, B. and Daniel, P.T.
Journal of Clinical Oncology 19 : 2272-2281. 1 January 2001

1999

Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Sturm, I., Koehne, C.H., Wolff, G., Petrowsky, H., Hillebrand, T., Hauptmann, S., Lorenz, M., Doerken, B. and Daniel, P.T.
Journal of Clinical Oncology 17 : 1364-1374. 1 May 1999

1998

Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study.
Reichardt, P., Tilgner, J., Hohenberger, P. and Doerken, B.
Journal of Clinical Oncology 16 (4): 1438-1443. April 1998

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Koehne, C.H., Schoeffski, P., Wilke, H., Kaeufer, C., Andreesen, R., Ohl, U., Klaasen, U., Westerhausen, M., Hiddemann, W., Schott, G., Harstick, A., Bade, J., Horster, A., Schubert, U., Hecker, H., Doerken, B. and Schmoll, H.J.
Journal of Clinical Oncology 16 (2): 418-426. February 1998

1997

Role of cranial radiotherapy for childhood T-cell acute lymphobalstic leukemia with high WBC count and good response to prednisone.
Conter, V., Schrappe, M., Arico, M., Reiter, A., Rizzari, C., Doerdelmann, M., Valsecchi, M.G., Zimmermann, M., Ludwig, W.D., Basso, G., Masera, G. and Riehm, H.
Journal of Clinical Oncology 15 (8): 2786-2791. August 1997

Treatment of brain metastases in patients with testicular cancer.
Bokemeyer, C., Nowak, P., Haupt, A., Metzner, B., Koehne, H., Hartmann, J.T., Kanz, L. and Schmoll, H.J.
Journal of Clinical Oncology 15 (4): 1449-1454. April 1997

1995

Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Koehne, C.H., Hiddemann, W., Schueller, J., Weiss, J., Lohrmann, H.P., Schmitz-Huebner, U., Bodenstein, H., Schoeber, C., Wilke, H., Grem, J. and Schmoll, H.J.
Journal of Clinical Oncology 13 : 1201-1208. 1 January 1995

Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Muenster Group.
Reiter, A., Schrappe, M., Parwaresch, R., Henze, G., Mueller-Weihrich, S., Sauter, S., Sykora, K.W., Ludwig, W.D., Gadner, H. and Riehm, H.
Journal of Clinical Oncology 13 : 359-372. 1 January 1995